PMN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ProMIS Neurosciences Inc (PMN) is not a strong buy at this moment for a beginner investor with a long-term strategy. The financial performance is weak, with significant losses in net income and EPS, and no revenue growth. While there is insider buying, which is a positive sign, the lack of strong technical signals, negative pre-market movement, and no recent news or congress trading data make it prudent to hold off on investing right now.
The MACD is positive but contracting, RSI is neutral at 69.022, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level of 15.6, with key support at 12.869 and resistance at 18.331. Pre-market price is down 2.47%, suggesting bearish sentiment.
Insiders are buying significantly, with a 56836.08% increase in buying activity over the last month. The company's Alzheimer's candidate, PMN310, is advancing toward key clinical milestones with pivotal data readouts expected in 2026.
Pre-market price is down 2.47%, and there is no recent news or congress trading data to drive positive sentiment.
In Q3 2025, the company reported no revenue growth (0% YoY), a net income loss of -11,580,126 (-224.84% YoY), and a significant drop in EPS to -5.93 (-176.91% YoY). Gross margin remained unchanged at 0%.
Guggenheim analyst Eddie Hickman maintains a Buy rating but lowered the price target from $6 to $5, citing progress in the company's Alzheimer's candidate, PMN310, toward key clinical milestones in 2026.
